Harmony Biosciences vs Ionis Pharmaceuticals
HRMY and IONS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HRMY and IONS compare
Ionis Pharmaceuticals is the larger company, worth 2.3 times as much as Harmony Biosciences ($4.5B against $1.9B).
Harmony Biosciences grew revenue faster over the last twelve months (24.3% versus −7.4% for Ionis Pharmaceuticals).
Harmony Biosciences keeps more of each dollar of sales as profit, with a net margin of 18.9% compared with −64.7% at Ionis Pharmaceuticals.
Harmony Biosciences scores higher on the StockData Score (18 against 4 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HRMY | IONS |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $4.5B |
| Share price | $33.01 | $26.96 |
| Change, 1 year | −3.0% | −62.3% |
| Change, 5 years | −12.1% | −7.2% |
| Beta (5Y) | 1.11 | 0.60 |
| Employees | 293 | 1,402 |
| StockData Score | ||
| Total score | 18 (better) | 4 |
| Valuation score | 6 (better) | 1 |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 10.7× | – |
| P/S | 2.0× (better) | 5.1× |
| P/B | 1.9× (better) | 10.2× |
| EV/EBITDA | 6.1× | – |
| FCF yield | – | −12.5% |
| Fair value | $53.99 | $27.86 |
| Margin of safety | 38.9% (better) | 3.2% |
| Growth | ||
| Revenue growth (TTM) | 24.3% (better) | −7.4% |
| Revenue growth, 5Y average | 40.3% (better) | 5.3% |
| Net income growth (TTM) | 0.20% | – |
| EPS growth (TTM) | −0.32% | – |
| Profitability | ||
| Gross margin | 75.4% | 98.2% (better) |
| Operating margin | 24.0% (better) | −68.0% |
| Net margin | 18.9% (better) | −64.7% |
| FCF margin | – | −64.2% |
| Return on equity | 20.5% (better) | −105% |
| Return on invested capital | 40.1% | – |
| Financial health | ||
| Debt / equity | 0.15 | – |
| Net debt / EBITDA | −2.23 | – |
| Interest coverage | 17.1× (better) | −31.6× |
| Current ratio | 3.48 | 7.89 (better) |
| Altman Z-score | 5.12 (better) | 0.23 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 93.0% | 108% |
| Held by insiders | 12.1% | 0.81% |
| Insider net buying, 12 months | −$5.8M (better) | −$114M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 13.0% | 12.8% |
Go deeper
- HRMY stock overview
- HRMY income statement
- HRMY valuation and score
- IONS stock overview
- IONS income statement
- IONS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.